{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:05:01Z","timestamp":1793325901286,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to investigate the prognostic significance of pretreatment dynamic contrast-enhanced (DCE)-MRI parameters concerning tumor response following induction immunochemotherapy and survival outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) who underwent immunotherapy-based multimodal treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>\n                      Unresectable stage III NSCLC patients treated by induction immunochemotherapy, concurrent chemoradiotherapy (CCRT) with or without consolidative immunotherapy from two prospective clinical trials were screened. Using the two-compartment Extend Tofts model, the parameters including K\n                      <jats:sup>trans<\/jats:sup>\n                      , K\n                      <jats:sub>ep<\/jats:sub>\n                      , V\n                      <jats:sub>e<\/jats:sub>\n                      , and V\n                      <jats:sub>p<\/jats:sub>\n                      were calculated from DCE-MRI data. The apparent diffusion coefficient was calculated from diffusion-weighted-MRI data. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to assess the predictive performance of MRI parameters. The Cox regression model was used for univariate and multivariate analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      111 unresectable stage III NSCLC patients were enrolled. Patients received two cycles of induction immunochemotherapy and CCRT, with or without consolidative immunotherapy. With the median follow-up of 22.3 months, the median progression-free survival (PFS) and overall survival (OS) were 16.3 and 23.8 months. The multivariate analysis suggested that Eastern Cooperative Oncology Group score, TNM stage and the response to induction immunochemotherapy were significantly related to both PFS and OS. After induction immunochemotherapy, 67 patients (59.8%) achieved complete response or partial response and 44 patients (40.2%) had stable disease or progressive disease. The K\n                      <jats:sup>trans<\/jats:sup>\n                      of primary lung tumor before induction immunochemotherapy yielded the best performance in predicting the treatment response, with an AUC of 0.800. Patients were categorized into two groups: high-K\n                      <jats:sup>trans<\/jats:sup>\n                      group (n=67, K\n                      <jats:sup>trans<\/jats:sup>\n                      \uff1e164.3\u00d710\n                      <jats:sup>\u22123<\/jats:sup>\n                      \/min) and low-K\n                      <jats:sup>trans<\/jats:sup>\n                      group (n=44, K\n                      <jats:sup>trans<\/jats:sup>\n                      \u2264164.3\u00d710\n                      <jats:sup>\u22123<\/jats:sup>\n                      \/min) based on the ROC analysis. The high-K\n                      <jats:sup>trans<\/jats:sup>\n                      group had a significantly higher objective response rate than the low-K\n                      <jats:sup>trans<\/jats:sup>\n                      group (85.1% (57\/67) vs 22.7% (10\/44), p&lt;0.001). The high-K\n                      <jats:sup>trans<\/jats:sup>\n                      group also presented better PFS (median: 21.1 vs 11.3 months, p=0.002) and OS (median: 34.3 vs 15.6 months, p=0.035) than the low-K\n                      <jats:sup>trans<\/jats:sup>\n                      group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Pretreatment K\n                      <jats:sup>trans<\/jats:sup>\n                      value emerged as a significant predictor of the early response to induction immunochemotherapy and survival outcomes in unresectable stage III NSCLC patients who underwent immunotherapy-based multimodal treatments. Elevated K\n                      <jats:sup>trans<\/jats:sup>\n                      values correlated positively with enhanced treatment response, leading to extended PFS and OS durations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-008574","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T10:45:15Z","timestamp":1719139515000},"page":"e008574","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Correlation of K\n                    <sup>trans<\/sup>\n                    derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02573506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03900117","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"DaQuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SongRan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PengXin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiYang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"United Imaging Healthcare, ShangHai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongQuan","family":"Ye","sequence":"additional","affiliation":[{"name":"United Imaging of Healthcare America, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhou","sequence":"additional","affiliation":[{"name":"SuZhou TongDiao Company, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiHang","family":"Jiang","sequence":"additional","affiliation":[{"name":"SuZhou TongDiao Company, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaoHan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoQiang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChuanMiao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-3756","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,23]]},"reference":[{"key":"2025100308424140000_12.6.e008574.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer Immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"2025100308424140000_12.6.e008574.2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100308424140000_12.6.e008574.3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in Resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100308424140000_12.6.e008574.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.050","article-title":"Lba1 Checkmate 77t: phase III study comparing Neoadjuvant Nivolumab (NIVO) plus chemotherapy (Chemo) vs Neoadjuvant placebo plus Chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, Resectable stage II\u2013IIIB NSCLC","volume":"34","author":"Cascone","year":"2023","journal-title":"Annals of Oncology"},{"key":"2025100308424140000_12.6.e008574.5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2023.02.017","article-title":"Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer","volume":"178","author":"Zeng","year":"2023","journal-title":"Lung Cancer"},{"key":"2025100308424140000_12.6.e008574.6","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.491","article-title":"Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial","volume":"11","author":"Laza-Briviesca","year":"2021","journal-title":"Clin Transl Med"},{"key":"2025100308424140000_12.6.e008574.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1200"},{"key":"2025100308424140000_12.6.e008574.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004708","article-title":"MRI techniques for immunotherapy monitoring","volume":"10","author":"Lau","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100308424140000_12.6.e008574.9","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150431","article-title":"Magnetic resonance imaging in lung: a review of its potential for radiotherapy","volume":"89","author":"Kumar","year":"2016","journal-title":"Br J Radiol"},{"key":"2025100308424140000_12.6.e008574.10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.21037\/tlcr.2017.09.02","article-title":"Magnetic resonance imaging in precision radiation therapy for lung cancer","volume":"6","author":"Bainbridge","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2025100308424140000_12.6.e008574.11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.semcancer.2020.12.005","article-title":"Integrated imaging and molecular analysis to decipher tumor Microenvironment in the era of Immunotherapy","volume":"84","author":"Wu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025100308424140000_12.6.e008574.12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2022.01.042","article-title":"Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent Chemoradiotherapy","volume":"168","author":"Wang","year":"2022","journal-title":"Radiother Oncol"},{"key":"2025100308424140000_12.6.e008574.13","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1007\/s00330-023-09813-8","article-title":"Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer","volume":"33","author":"Bao","year":"2023","journal-title":"Eur Radiol"},{"key":"2025100308424140000_12.6.e008574.14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2020.03.013","article-title":"Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune Checkpoint inhibitors in patients with non-small-cell lung cancer","volume":"143","author":"Karayama","year":"2020","journal-title":"Lung Cancer"},{"key":"2025100308424140000_12.6.e008574.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2569"},{"key":"2025100308424140000_12.6.e008574.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.11.007"},{"key":"2025100308424140000_12.6.e008574.17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jmri.25018","article-title":"Comparison of Intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions","volume":"43","author":"Yuan","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"2025100308424140000_12.6.e008574.18","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2021.13039","article-title":"Dynamic contrast-enhanced MRI as a Predictor of programmed death Ligand-1 expression in patients with oral squamous cell carcinoma","volume":"22","author":"Tekiki","year":"2021","journal-title":"Oncol Lett"},{"key":"2025100308424140000_12.6.e008574.19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11547-019-01081-1","article-title":"Histogram analysis of DCE-MRI for Chemoradiotherapy response evaluation in locally advanced Esophageal squamous cell carcinoma","volume":"125","author":"Sun","year":"2020","journal-title":"Radiol Med"},{"key":"2025100308424140000_12.6.e008574.20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00330-018-5719-1","article-title":"Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to Chemoradiotherapy for Rectal cancer","volume":"29","author":"Gollub","year":"2019","journal-title":"Eur Radiol"},{"key":"2025100308424140000_12.6.e008574.21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.radonc.2015.05.001","article-title":"Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced Cervical cancer","volume":"115","author":"Lund","year":"2015","journal-title":"Radiother Oncol"},{"key":"2025100308424140000_12.6.e008574.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-016-4692-9"},{"key":"2025100308424140000_12.6.e008574.23","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.24835"},{"key":"2025100308424140000_12.6.e008574.24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated intensity modulated radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer: A phase II prospective clinical trial (Gasto1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"2025100308424140000_12.6.e008574.25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijrobp.2023.04.021","article-title":"Hypofractionated radiotherapy followed by Hypofractionated boost with weekly concurrent chemotherapy for unresectable stage III non-small cell lung cancer: results of a prospective phase II study (GASTO-1049)","volume":"117","author":"Zhou","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100308424140000_12.6.e008574.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2025100308424140000_12.6.e008574.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100308424140000_12.6.e008574.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2025100308424140000_12.6.e008574.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100308424140000_12.6.e008574.30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/j.semnuclmed.2022.04.010","article-title":"FDG PET\/CT for evaluation of immunotherapy response in lung cancer patients","volume":"52","author":"L\u00e9ger","year":"2022","journal-title":"Semin Nucl Med"},{"key":"2025100308424140000_12.6.e008574.31","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2025100308424140000_12.6.e008574.32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2028962","article-title":"A short-term follow-up CT based radiomics approach to predict response to Immunotherapy in advanced non-small-cell lung cancer","volume":"11","author":"Gong","year":"2022","journal-title":"Oncoimmunology"},{"key":"2025100308424140000_12.6.e008574.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0895"},{"key":"2025100308424140000_12.6.e008574.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1"},{"key":"2025100308424140000_12.6.e008574.35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212456"},{"key":"2025100308424140000_12.6.e008574.36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41416-018-0342-0","article-title":"Multiparametric magnetic resonance imaging in the assessment of anti-egfrviii chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma","volume":"120","author":"Wang","year":"2019","journal-title":"Br J Cancer"},{"key":"2025100308424140000_12.6.e008574.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01489-6","article-title":"Quantitative Multiparametric MRI predicts response to neoadjuvant therapy in the community setting","volume":"23","author":"Virostko","year":"2021","journal-title":"Breast Cancer Res"},{"key":"2025100308424140000_12.6.e008574.38","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/0284186X.2018.1473637","article-title":"DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to Neoadjuvant chemoradiotherapy for esophageal cancer","volume":"57","author":"Heethuis","year":"2018","journal-title":"Acta Oncol"},{"key":"2025100308424140000_12.6.e008574.39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jmri.26254","article-title":"Response to neoadjuvant chemoradiotherapy for locally advanced rectum cancer: texture analysis of dynamic contrast-enhanced MRI","volume":"49","author":"Zou","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"2025100308424140000_12.6.e008574.40","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1007\/s00330-020-06849-y","article-title":"High Spatiotemporal resolution dynamic contrast-enhanced MRI improves the image-based discrimination of Histopathology risk groups of peripheral zone prostate cancer: a supervised machine learning approach","volume":"30","author":"Winkel","year":"2020","journal-title":"Eur Radiol"},{"key":"2025100308424140000_12.6.e008574.41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ijrobp.2019.03.002","article-title":"DCE-MRI and quantitative histology reveal enhanced vessel maturation but impaired perfusion and increased hypoxia in Bevacizumab-treated Cervical carcinoma","volume":"104","author":"Hauge","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100308424140000_12.6.e008574.42","doi-asserted-by":"crossref","first-page":"108669","DOI":"10.1016\/j.ejrad.2019.108669","article-title":"Histogram analysis parameters derived from DCE-MRI in head and neck squamous cell cancer - associations with Microvessel density","volume":"120","author":"Meyer","year":"2019","journal-title":"European Journal of Radiology"},{"key":"2025100308424140000_12.6.e008574.43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11547-018-0978-0","article-title":"Dynamic contrast-enhanced magnetic resonance imaging in locally advanced Rectal cancer: role of perfusion parameters in the assessment of response to treatment","volume":"124","author":"Ciolina","year":"2019","journal-title":"Radiol Med"},{"key":"2025100308424140000_12.6.e008574.44","doi-asserted-by":"crossref","first-page":"20200751","DOI":"10.1259\/bjr.20200751","article-title":"Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer","volume":"93","author":"Guo","year":"2020","journal-title":"BJR"},{"key":"2025100308424140000_12.6.e008574.45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003125","article-title":"Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma","volume":"9","author":"Lau","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100308424140000_12.6.e008574.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03379-6"},{"key":"2025100308424140000_12.6.e008574.47","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3758"},{"key":"2025100308424140000_12.6.e008574.48","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5301\/tj.5000612","article-title":"Diffusion-weighted imaging in evaluating the efficacy of concurrent chemoradiotherapy in the treatment of non-small cell lung cancer","volume":"104","author":"Xu","year":"2018","journal-title":"Tumori"},{"key":"2025100308424140000_12.6.e008574.49","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.20795"},{"key":"2025100308424140000_12.6.e008574.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1331-4","article-title":"DCE-MRI of patient-derived Xenograft models of uterine cervix carcinoma: associations with parameters of the tumor Microenvironment","volume":"15","author":"Hauge","year":"2017","journal-title":"J Transl Med"},{"key":"2025100308424140000_12.6.e008574.51","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-022-01516-0","article-title":"Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor Microenvironment","volume":"24","author":"Wang","year":"2022","journal-title":"Breast Cancer Res"},{"key":"2025100308424140000_12.6.e008574.52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jitc-2022-006092","article-title":"Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI","volume":"11","author":"Hoffmann","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100308424140000_12.6.e008574.53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers13071724","article-title":"The tumour vasculature as a target to modulate leucocyte trafficking","volume":"13","author":"Zhao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100308424140000_12.6.e008574.54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1919764117"},{"key":"2025100308424140000_12.6.e008574.55","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2705"},{"key":"2025100308424140000_12.6.e008574.56","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12451"},{"key":"2025100308424140000_12.6.e008574.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.07.004"},{"key":"2025100308424140000_12.6.e008574.58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2025100308424140000_12.6.e008574.59","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025100308424140000_12.6.e008574.60","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-018-0241-4","article-title":"Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer","volume":"19","author":"Jackute","year":"2018","journal-title":"BMC Immunol"},{"key":"2025100308424140000_12.6.e008574.61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0069"},{"key":"2025100308424140000_12.6.e008574.62","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3RU1018-378RR"},{"key":"2025100308424140000_12.6.e008574.63","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.7150\/thno.47137","article-title":"Usp7 targeting modulates anti-tumor immune response by reprogramming tumor-associated macrophages in lung cancer","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"key":"2025100308424140000_12.6.e008574.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.05.002"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:42:53Z","timestamp":1759506173000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,23]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jitc-2023-008574"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008574","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}